No announcement yet.

Red Algae antiviral properties research

  • Filter
  • Time
  • Show
Clear All
new posts

  • Red Algae antiviral properties research

    Thank you Shannon.

    Red Algae antiviral properties


    Antiviral carbohydrates from marine red algae


    Michael Neushul
    Department of Biological Sciences, University of California, Santa Barbara,
    93106, USA and Neushul Mariculture Incorporated, 475 Kellog Way, Goleta,
    CA, 93117, USA

    Key words: AIDS, antiviral, herpes, red algae, seaweed, sulfated


    It is possible that heparin-like sulfated polysaccharides from red algae, or
    fractions thereof, might be found to be low-cost, broad-spectrum antiviral
    agents. The prevailing view among virologists has been that sulfated
    polysaccharides inhibit viral action by acting only at the surfaces of cells.
    This perception now is changing with the finding that both the herpes virus
    (containing DNA) and immunodeficiency virus (containing RNA) are inhibited
    by sulfated polysaccharides that act within the cell as well as external to it.
    Aqueous extracts of many red algae are active against retroviruses.
    Carrageenan, a common cell wall polysaccharide from red algae, is co-
    internalized into infected cells with Herpes simplex virus (HSV), inhibiting
    the virus. Carrageenan also interferes with fusion (syncytium formation)
    between cells infected with the human immunodeficiency virus (HIV) and
    inhibits the specific retroviral enzyme reverse transcriptase.


    Our increasing scientific understanding of the world around us is gained
    through a series of different, and seemingly unrelated discoveries. But
    collectively these discoveries are related, in that they support the concept
    of biological specificity. Silverstein (1989), in his very readable book on
    the history of immunology, reviews the philosophical roots of the concept
    of biological specificity and shows how it has influenced the development
    of modern immunological thought.

    Those who have studied the growth, development and reproduction of marine
    red algae know that secondary pit connection formation involves the fusion of
    very specific cells. In the process of fertiliztion in these plants there is a
    specific union of spermatium and trichogyne (Fetter & Neushul, 1981), and
    this is followed by complex post-fertilization events involving very specific
    cell fusions. Is it possible that the walls of the cells involved in these
    processes contain chemically-indentifiable molecules that determine the
    specificity, as is the case in antigen-antibody interactions? Obviously food-
    scientists find it useful that specific carrageenans bind to specific milk
    proteins. It is possible that this specificity could be useful therapeutically as
    well? If so, then in addition to the large-scale cultivation of marine red
    algae for food and phycocolloids, we would see them cultivated as a source of
    pharmaceuticals. This would be interesting particularly if they served to
    palliate or even hopefully cure virally-caused diseases.

    At one time it was thought that viruses were so closely associated with their
    host cells that it would be difficult, if not impossible, to destroy one and
    not the other. However with the discovery of the first antiviral drugs in 1950
    and their first clinical use in 1962, it became clear that antiviral therapy
    was possible (Bauer, 1985). With the development of the plaque inhibition test
    (Rada et al., 1960), it became possibile to test large numbers of compounds
    for their antiviral activity. It soon was discovered that agar (a sulfated
    polysaccharide extracted from marine red algae) used in plaque assays was
    itself antiviral (Gonzales et al., 1987). But agar was thought to inhibit
    viral attachment to uninfected cells, rather than inhibiting the virus within
    the infected cell. It also was found that heparainized blood plasma, and
    heparin alone, inhibited some Rous Sarcoma Virus strains (Solomon et al.,
    1966). The idea that viral-binding carbohydrates inhibit by acting outside the
    cell has prevailed among most virologists. Consequently, the discovery that
    agar and other aqueous extracts of marine red algae have antiviral activity
    stimulated little interest. Recent work on these aqueous extracts, on specific
    carbohydrates in them (carrageenans) and on other sulfated polysaccharides
    like dextran sulfate and heparin (Baba et al., 1988; MItsuya et al., 1988; Ueno
    & Kuno, 1987) suggests that these molecules may inhibit both DNA- and RNA-
    virus infections and may operate both outside of, and within infected cells.

    An antiviral compound usually is identified by first gaining an understanding
    of a virus-specific process (cellular attachment, genome uncoating, the action
    of viral enzymes) and then showing how the compound or drug inhibits the
    process. Then by understanding the relationship between the molecular
    structure of the drug and the molecules with which it interacts, one can
    produce and test related compounds. In this way it was found that synthetic
    nucleosides (first produced as anti-neoplastic agents) either inhibit viral DNA
    or RNA polymerasees, or act as chain terminators after being incorporated
    into nucleic acids (Wood & Geddes, 1987; Muller, 1979)

    Antiviral nucleosides that have been found to be useful for the treatment of
    herpes virus infections are Idozuridine (IDU), trifluridine (TBT), virabaine
    (ara-A), bromovinyldozyuridine (BVDU), fluoriodoaracytosine (FIAC),
    ganciclovir (DHPG), and acyclovir. Another synthetic nucleoside, Zidovudine
    (AZT) has been found to suppress replication of the human immunodeficiency
    virus, the causal agent of AIDS. Non-nucleoside antivirals include the
    amantadine, rimantadine, phosphonoformate and ampligen.

    The selection of an effective antiviral compound is complicated by the fact
    that most antiviral agents have been studies by many different investigators
    using different virus strains, cell culture systems and assay procedures.
    Consequently, their relative potency usually is not known. Comparative
    efficacy studies, using the same cell culture system, have been conducted
    for the herpes simplex virus by De Clercq et al. (1980), and data for the
    effects of antivirals on human immunodeficiency virus have been assembled
    by Abrams et al. (1988).

    Algal extracts with antiviral activity

    The search for either useful phycocolloids or pharmacologically active
    substances in marine algae usually begins with screening studies that focus
    on a specific flora (Blunden et al., 1981; Whyte et al., 1984; Ragan, 1984;
    Pesando & Caram, 1984; Hodgson; 1984, Untawale et al., 1977; Hornsey
    & Hide, 1974 Dhargalkar et al., 1980). Studies of California red algae by
    Ehresmann et al. (1977, 1979), Hatch et al., (1979) and Richards et al.
    (1978) in a search for anti-herpetic substances have been particularly
    interesting. The use of these plants as botanical agents to treat viral
    infection resulted in four patents. The first two (U.S. patent numbers
    4,162,308 and 4,162,309) (Calvin & Ellis, 1979) used aqueous extracts
    of Neodilsea americana and N. integra. The third patent is particularly well
    documented, and involves the use of Cryptosiphonia woodii (Nonomura,
    1985) (U.S. patent number 4,522,814). In this instance clinical efficacy
    was clearly shown. The fourth patent (Neushul, 1988) (U.S. patent number
    4,783,446) is for the use of carrageenan and other sulfated polysaccharides
    for the treatment of diseases (including AIDS) caused by retroviral infection.
    The pharmaceutical industry has been slow to become interested in these
    discoveries, because of the technical difficulties involved in working with
    carbohydrates and the research costs involved. Hopefully recent screening
    stuides may stimulate future interest (Alarcon et al.,1984), as will our
    growing appreciation of the immunomodulating effects of natural and synthetic
    heparinods (Dziarski, 1989).

    Carrageenan as a bioactive molecule

    There is considerable evidence that carrageenans bind to and modulate cell-cell
    interactions of various kinds including sperm-egg fusion in the brown alga
    Fucus, fertilization in sea urchins, hamsters and guinea pigs, embryogenesis
    in the green alga Volvox, aggregation of isolated sponge cells, the inhibition
    of lymphocyte recirculation, lymphocyte binding to high endothelial venules
    and autorosetting (Chong & Parish, 1987).

    Degraded carrageenan has long been known to be a potent inflammatory agent
    in vivo (Abraham et al., 1985; Selin & Oyarzabal, 1988). Hydrolyzed
    carrageenans have been used to experimentally induce intestinal inflammation
    in many animal models of inflammatory bowel diseases (Delahunty et al.,1987).
    Carrageenans can have long-lasting effects on the immune system (Thomas &
    Fowler, 1981). The extensive studies of carrageenan-induced colitis by
    Onderdonk and his co-workers are particularly interesting in that carrageenan
    did not cause intestinal inflammation and ulceraton in germ-free guinea pigs,
    but when specific strains of the intestinal bacterium, Bacteriodes, and
    carrageenan both were present in the lumen, inflammation and ulceration
    was induced. In this instance it acts as a adjuvant (Onderdonk, 1985).

    Red algal extracts and carrageenan as antivral agents

    Because of the severity of the present AIDS epidemic and the debilitating
    effects of herpes virus infections, it was important to re-examine the
    antiviral effects of red algal extracts, even if they have been of little
    interest to virologists. In attempting to confirm the findings of others
    who have studied the antiviral effects of aqueous extracts of seaweeds,
    we collected and screened 39 Californian marine red algal species for
    activity against Herpes simplex virus in a simple assay where extracts
    were added prior to infecting the target cells. Further tests of extracts
    of some of these species were run for us by Burroughs Wellcome. These
    first studies showed that there was potent anti-retroviral activity in an
    aqueous extract of Schizymenia pacifica against a murine leukemia virus.
    This later was verified by colleagues in England and Japan. Stuides as early
    as that of Solomon et al.,(1966) and other work in the 1970s (Schaffrath et
    al., 1976) showed that sulfated oligo- or poly-saccharide compounds
    suppressed retroviral replication and inhibited viral reverse transcriptases.
    Tests run in Japan, using a reverse-transcriptases inhibition assay, showed
    that nearly all of the 39 species we had collected contained an inhibitory
    substance (Table 1).

    It is intersting that although at least one carrageenophyte (Ahnfeltia
    gigartionides) was only mildly active, and some agarophytes (Gracilaria,
    Laurencia) was active, most of the carrageenophytes were active. This
    suggests that a common immunomodulatory cell wall carbohydrate, like
    carrageenan, was likely to be the active component. Further studies of the
    aqueous extract and fractions thereof showed that carrageenan was indeed
    the active antiviral component (Nakashima et al., 1987a, 1987b). Studies
    of other heparinoids, like dextran sulflate, also supported the contention that
    sulfated polysaccharides can have a potent anti-retroviral effect in vitro
    (Ueno & Kuno, 1987; Nagumo & Hoshino, 1988; Mitsuya et al., 1988; Baba et al.
    , 1988). Clinical tests with AIDS patients given intravenous and
    enterically-coated dexran sulfate at San Francisco General Hospital also
    have been encouraging (Abrams et al., 1988).


    If sulfated polysaccharides from red algae do inhibit many different viruses,
    then it will be essential to understand the molecular basis for virus-specific
    inhibition in each case. This will not be an easy task. Diverse viruses,
    infecting different kinds of cells, provide many targets for inhibition that
    will have to be indentified. The antiviral molecule also will be hard to find
    since there are a number of different kinds of carrageenan, and bioactivity
    likely is produced by a specific, sulfated fraction. The extensive, often
    contradictory literature on the inflammatory effects of carrageenans
    illustrates the problems that can be anticipated. Those studying carrageenan-
    induced inflammation almost always use off-the-shelf samples of carrageenan
    purchased from those who extract it for use as a food additive. Attempts to
    repeat the first experiments, using other carrageenan samples, often fail,
    probably because of differences in this carrageenan. The life-history stage
    of a red algal member of a family Gigartinaceae determines whether it
    produced lambda or kappa carrageenan; consequently extracts from harvests
    containing both life-history stages (gamete- and spore-producing) will have
    varying amounts of these two carrageenan types. Secondly, the ratio of
    kappa to iota carrageenan in a plant can vary greatly, even among species
    of the same genus. The only way to be sure that one is obtaining a specific
    carrageenan type is to carefully sort and identify the species and life-history
    stage of the source alga. Because of taxonomic uncertainties it also is
    important to file voucher specimens. If one starts from a botanically-
    indentified source plant, and then chemically identifies the polysaccharide and
    fractions thereof being screened, there is some likelihood that one's results
    can be repeated by others. There is also an opportunity to gain an appreciation
    of the molecular interactions that produce the antiviral activity. Attempts
    should be made to determine the cellular site of action. As noted earlier,
    dextran sulfate has been reported to inhibit syncytium formation (Baba et al.,
    1988), acting external to the cell. Preliminary tests, using a new syncytium-
    formation assay (Nara & Fischinger, 1988), showed that iota carrageenan also
    inhibits syncytium formation by HIV-infected cells. There is some evidence
    that dextran sulfate may be of some use clinically (Abrams et al., 1988).
    Carrageenans, as noted earlier, may be taken up by infected cells.

    The suggestion that heparinoid-receptors may be involved in interactions
    between lymphocytes and macrophages might exlain some of the
    immunodulatory effects reported for carrageenan (Chong & Parish, 1987;
    Dziarski, 1989). Preliminary studies of degraded carrageenan have shown
    that in combination with IL-4, carrageenan stimulates cell division by cultured
    murine mast cells (K. Smith, unpublished). Clearly it will be important to
    identify and characterize carrageenan and other heparnoid receptors to see
    if binding to such receptor triggers a specific cellular response sequence.
    It seems worthwhile to determine if red algal polysaccharides and other
    heparinoids are clinically useful broad-spectrum antiviral agents, or if
    they might be used clincially to enhance the generation of tumor-specific
    cytotoxic cells, or serve in other ways as immunomodulatory agents.


    This research was supported by the National Institutes of Health (SBIR
    program, awards to Neushul Mariculture Incorporate) and was under
    the able direction of R. J. Lewis, who also provided a helpful review
    of this paper.


    Abraham, R., K. F. Benitz, R. Mankes & I. Rosenblum, 1985. Chronic and
    subchronic effects of various forms of carrageenan in rats. Ecotoxicol.
    Envir. Saf. 10: 173-183.
    Abrams, D., M. Gottlieb, M. Grieco, M. Speer & S. Bernstein, 1988.
    AIDS/HIV Experimental Treatment Directory. American Foundation for
    Aids Research, N.Y., 188pp.
    Alarcon, B., J. C. Lacal, J. M. Fernandez-Sousa & L. Carrasco, 1984.
    Screening for new compounds with anti-herpes activity. Antiviral Res.
    4: 231-244.
    Bauer D. H., 1985. A history of the discovery and clinical application of
    antiviral drugs. Br. Med. Bull. 41: 309-314.
    Baba, M., R. Pauwels, J. Balzarini, J. Arnout, J. Desmyter & E. De-Clercq,
    1988. Mechanism of inhibitory effect of dextran sulfate and heparin on
    replication of human immunodeficiency virus in vitro. Proc. Natl. Acad.
    Sci. USA. 85: 6132-6136.
    Blunden, G., C. J. Barwell, K. J. Fidgen & K. Jewers, 1981. A survey of
    some British marine algae for anti-influenza virus activity. Bot. mar.
    24: 267-272.
    Calvin, N. I. & R. J. Ellis, 1979. Water Soluble Extracts of Certain Marine
    Red Algae and Processes for Use Thereof. U.S. Patents 4,162,308 and
    Chong, A. S.-F. & C. R. Parish, 1985. Non-immune lymphocyte-macrophage
    interaction II. Evidence that the interaction involves sulfated polysaccharide
    recognition. Cell. Immunol. 92: 277-289.
    De Clercq, E., J. Descamps, G. Verhelst, R. Walker, A. Jones, P. Torrence &
    D. Shugar, 1980. Comparative efficacy of antiherpes drugs against
    different strains of Herpes simplex virus. J. Inf. Dis. 141: 563-574.
    Dharagalkar, V. K., T. G. Jagtap & A. G. Untawale, 1980. Comparative
    efficacy of antiherpes drugs against different strains of Herpes simplex virus.
    J. Inf. Dis. 141: 563-574.
    Delahunty, T., L. Recher & D. Hollander, 1987. Intestinal permeability
    changes in rodents: A possible mechanism for degraded carrageenan-induced
    colitis. Fd Chem. Toxic. 25: 113-118.
    Dziarski, R., 1989. Enhancement of mixed leukocyte reaction and cytotoxic
    antitumor responses by heparin. J. Immunol. 143: 356-365.
    Ehresmann, D. W., E. F. Deig, M. T. Hatch, L. H. Di Salvo and N. A. Vedros.
    1977. Antiviral substances from California marine algae. J. Phycol.
    13: 37-40.
    Ehresmann, D. W., E. F. Deig, M. T. Hatch, 1979. Antiviral properties of
    algal polysaccharides and related compounds. In H. A. Hoppe, T. Levring &
    R. Tanaka (Eds), Marine Algae in Pharmaceutical Science, W. de Gruyter,
    N.Y.: 293-302
    Fetter, R. & M. Neushul, 1981. Studies on developing and released spermatia
    in the red alga. Tiffaniella snydreae (Rhodophyta). J. Phycol. 17: 141-159.
    Gonzalez, M. E., B. Alarcon & L. Carrasco, 1987. Polysaccharides as antiviral
    agents: Antiviral activity of carrageenan. Antimicrob. Agents Chemother.
    31: 1388-1393.
    Hatch, M. T., D. W. Ehresmann & E. F. Deig, 1979. Chemical characterization
    and therapeutic evaluation of anti-Herpesvirus polysaccharides from species
    of Dumontiaceae. In H. A. Hoppe, T. Levring & Y. Tanaka (eds). Marine Algae
    in Pharmaceutical Science. W. de Gruyter, N.Y.: 343-363.
    Hodgson, L. M., 1984. Antimicrobial and antineoplastic activity in some South
    Florida seaweeds. Bot. mar. 28: 387-390
    Hornsey, I. S. & D. Hide, 1974. The production of antimicrobial compounds by
    British marine algae. 1. Antibiotic producing marine algae. Br. phycol. J.
    9: 353-361.
    Mitsuya, H., D. J. Looney, S. Kuno, R. Ueno, F. Wong-Staal & S. Broder, 1988.
    Dextran sulfate suppression of viruses in the HIV family: inhibition of virion
    binding to CD4+ cells. Science 240: 646-649.
    Muller, W. E. G., 1979. Mechanisms of action and pharmacology: Chemical
    agents. In G. J. Galasso, T. C. Merigan & R. A. Buchanan (eds), Antiviral
    Agents and Viral Diseases of Man. Raven Press, N.Y.: 77-150.
    Nagumo, T. & H. Hoshino, 1988. Heparin inhibits infectivity of human
    immunodeficiency virus in vitro. Jpn. J. Cancer Res. (Gann) 79: 9.
    Nakashima, H, Y. Kido, N. Kobayashi, Y. Motoki, M. Neushul & N. Yamamoto,
    1987a. Antiretroviral activity in a marine red alga: reverse transcriptase
    inhibition by an aqueous extract of Schizymenia pacifica. J. Cancer Res. Clin.
    Oncol. 113: 413-416.
    Nakashima, H., Y. Kido, N. Kobayashi, Y. Motoki, M. Neushul & N. Yamamoto,
    1987b. Purification and characterization of an avian myeloblastosis and
    human immunodeficiency virus reverse transcriptase inhibitor, sulfated
    polysaccharides extracted from sea algae. Antimicrob. Agents Chemother.
    31: 1524-1528.
    Nara, P. L. & P. J. Fischinger, 1988. Quantitative infectivity for HIV-I and II.
    Nature 332: 469-470.
    Neushul, M., 1988. Method for the treatment of AIDS virus and other
    retroviruses. U.S. Patent no. 4,783,446.
    Nonomura, A. L., 1985. Composition of matter from Cryptosiphonia
    woodii useful for the treatment of Herpes Simples virus. United States
    Patent no 4,522,814.
    Onderdonk, A. B., 1985. Experiemental models for ulcerative colitis.
    Dig. Dis. Sci. (suppl.) 30: 40S-44S.
    Pesando, D. & B. Caram, 1984. Screening of marine algae from the French
    Mediterranean coast for antibacterial and antifungal activity. Bot. mar.
    28: 381-386.
    Rada, B., D. Blaskovic, F. Sorm & J. Skoda, 1960. The inhibitory effect of
    6-azauracil riboside on the multiplication of vaccinia virus. Experientia
    16: 487.
    Ragan, M. A., 1984. Bioactivities in marine genera of Atlantic Canada:
    The unexplored potential. Proc. N. S. Inst. Sci. 34: 83-112.
    Richards, J. T., E. R. Kern, L. Glasgow, J. Overall, E. Deig & M. Hatch, 1978.
    Antiviral activity of extracts from marine algae. Antimicrob. Agents
    Chemother. 14: 24-30.
    Schaffrath, D., H. W. Stuhslatz & H. Greiling, 1976. Interactions of
    glycosaminoglycans with DNA and RNA synthesizing enzymes in vitro.
    Z Physiol. Chem. 357: 499-508.
    Sellin, J. H. & H. Oyarzabal, 1988. Carrageenan-induced colitis alters
    ion transport in rabbit colon in vitro. In R. P. MacDermott (ed.),
    Inflammatory Bowel Disease: current status and future approach.
    Elsevier, N.Y.: 391-396.
    Silverstein, A. M., 1989. A History of Immunology. Academic Press,
    N.Y., 422pp.
    Solomon, J. J., K. A. Glatt & W. Okazaki, 1966. Inhibitory effect of
    heparin on Rous Sarcoma virus. J Bact. 92: 1855-1856.
    Thomson, A. W. & E. F. Fowler, 1981. Carrageenan: a review of its
    effects on the immune system. Agents Actions 11: 265-273.
    Ueno, R. & S. Kuno, 1987. Dextran sulphate, a potent anti-HIV in vitro
    having synergism with zidovudine. Lancet 1: 1379.
    Untawale, A. G., N. B. Bhosle & V. K. Dhargalkar, 1977. Properties of
    phycocolloid extracts from seaweeds of Goa. Ind. J. Mar. Sci. 6: 181-183.
    Whyte, J. N. C., R. E. Foreman & R. E. DeWreede, 1984. Phycocolloid
    screening of British Colulmbian red algae. Proc, int. Seaweed Symp. 11: 537-541.
    Wood, M. J. & A. M. Geddes, 1987. Antiviral Therapy. Lancet 1: 1189-1192.